Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 3Recruiting 2Completed 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 26INDUSTRY 5OTHER_GOV 2UNKNOWN 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Lymphoma, T-Cell, Peripheral 1HR+/HER2- Breast Cancer 1

Interventions

pembrolizumab 9Drug Therapy 9Bevacizumab 9Radiotherapy 8Carboplatin 8Oxaliplatin 7Cyclophosphamide 7Surgical Procedures, Operative 6Cisplatin 6Capecitabine 6tislelizumab 5Paclitaxel 5Fluorouracil 5Docetaxel 5Control Groups 5Nivolumab 4Immune Checkpoint Inhibitors 4Gemcitabine 4Endoscopic Mucosal Resection 4sintilimab 3fludarabine 3Trastuzumab 3Pemetrexed 3Neoadjuvant Therapy 3Leucovorin 3Laparoscopy 3Irinotecan 3Injections 3Hematologic Tests 3HMPL-013 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × OTHER_GOV × Epirubicin × Clear all
NCT06421948 2025-12-05

Linperlisib Combined With Chidamide in Patients With PTCL

Henan Cancer Hospital

Phase 1/2 Recruiting
134 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06860529 2025-06-23

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Henan Cancer Hospital

Phase 2 Recruiting
357 enrolled
Breast

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡